Scott Auerbach
Concepts (389)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Transplantation | 41 | 2026 | 726 | 7.750 |
Why?
| | Heart-Assist Devices | 21 | 2025 | 572 | 3.760 |
Why?
| | Heart Failure | 26 | 2025 | 2131 | 2.790 |
Why?
| | Graft Rejection | 13 | 2025 | 551 | 2.130 |
Why?
| | Graft Survival | 11 | 2025 | 522 | 2.020 |
Why?
| | Toxicity Tests | 7 | 2025 | 39 | 1.190 |
Why?
| | Gene Expression Profiling | 11 | 2025 | 1794 | 1.170 |
Why?
| | Muscular Dystrophy, Duchenne | 5 | 2025 | 92 | 1.130 |
Why?
| | Transcriptome | 12 | 2025 | 1029 | 1.130 |
Why?
| | Heart Defects, Congenital | 11 | 2025 | 887 | 1.120 |
Why?
| | Cardiomyopathies | 10 | 2025 | 335 | 1.100 |
Why?
| | Child | 58 | 2026 | 22725 | 1.070 |
Why?
| | Mutagens | 6 | 2025 | 26 | 1.010 |
Why?
| | Heart Diseases | 3 | 2023 | 340 | 1.010 |
Why?
| | Liver | 9 | 2025 | 1864 | 1.010 |
Why?
| | Glomerular Filtration Rate | 3 | 2026 | 775 | 0.990 |
Why?
| | Toxicogenetics | 5 | 2023 | 6 | 0.870 |
Why?
| | Carcinogens | 5 | 2025 | 126 | 0.830 |
Why?
| | Steroids | 2 | 2015 | 165 | 0.810 |
Why?
| | Kidney Transplantation | 3 | 2026 | 698 | 0.790 |
Why?
| | Myocarditis | 2 | 2023 | 99 | 0.790 |
Why?
| | Child, Preschool | 28 | 2026 | 11737 | 0.760 |
Why?
| | Renal Insufficiency, Chronic | 3 | 2025 | 637 | 0.710 |
Why?
| | Immunosuppressive Agents | 5 | 2025 | 859 | 0.680 |
Why?
| | Toxicology | 4 | 2025 | 46 | 0.670 |
Why?
| | Adolescent | 38 | 2026 | 22481 | 0.650 |
Why?
| | Registries | 15 | 2025 | 2238 | 0.650 |
Why?
| | Environmental Pollutants | 4 | 2025 | 165 | 0.630 |
Why?
| | Humans | 98 | 2026 | 143560 | 0.610 |
Why?
| | Organ Transplantation | 4 | 2024 | 252 | 0.610 |
Why?
| | Liver Neoplasms, Experimental | 2 | 2018 | 29 | 0.590 |
Why?
| | Small Molecule Libraries | 2 | 2017 | 107 | 0.590 |
Why?
| | Retrospective Studies | 25 | 2026 | 16741 | 0.560 |
Why?
| | Treatment Outcome | 20 | 2025 | 11365 | 0.540 |
Why?
| | Plant Preparations | 3 | 2025 | 37 | 0.530 |
Why?
| | Kidney Failure, Chronic | 1 | 2023 | 600 | 0.530 |
Why?
| | Infant | 22 | 2026 | 9981 | 0.530 |
Why?
| | Ventricular Dysfunction, Left | 2 | 2020 | 377 | 0.520 |
Why?
| | Exome | 1 | 2018 | 240 | 0.510 |
Why?
| | Coronary Artery Disease | 2 | 2020 | 722 | 0.500 |
Why?
| | Male | 48 | 2026 | 71500 | 0.500 |
Why?
| | Prosthesis-Related Infections | 1 | 2017 | 98 | 0.500 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2017 | 539 | 0.490 |
Why?
| | Disease Management | 1 | 2020 | 646 | 0.480 |
Why?
| | Cardiomyopathy, Dilated | 4 | 2022 | 340 | 0.480 |
Why?
| | Risk Factors | 16 | 2026 | 10644 | 0.470 |
Why?
| | Extracorporeal Membrane Oxygenation | 4 | 2022 | 353 | 0.460 |
Why?
| | Sequence Analysis, DNA | 1 | 2018 | 823 | 0.450 |
Why?
| | Follow-Up Studies | 10 | 2025 | 5308 | 0.440 |
Why?
| | Cardiology | 1 | 2017 | 287 | 0.440 |
Why?
| | Stroke | 1 | 2023 | 1213 | 0.430 |
Why?
| | Young Adult | 14 | 2024 | 13972 | 0.410 |
Why?
| | High-Throughput Screening Assays | 5 | 2020 | 161 | 0.410 |
Why?
| | Benchmarking | 5 | 2024 | 183 | 0.410 |
Why?
| | Myocardium | 3 | 2022 | 928 | 0.400 |
Why?
| | Female | 37 | 2026 | 77251 | 0.390 |
Why?
| | Sequence Analysis, RNA | 2 | 2014 | 447 | 0.380 |
Why?
| | Risk Assessment | 7 | 2025 | 3577 | 0.370 |
Why?
| | Histones | 1 | 2017 | 666 | 0.350 |
Why?
| | Kidney | 3 | 2026 | 1507 | 0.350 |
Why?
| | Biomarkers | 9 | 2025 | 4241 | 0.340 |
Why?
| | Postoperative Complications | 6 | 2025 | 2887 | 0.340 |
Why?
| | Echocardiography | 3 | 2022 | 652 | 0.330 |
Why?
| | DNA Damage | 5 | 2025 | 446 | 0.330 |
Why?
| | Gene Expression Regulation | 5 | 2025 | 2621 | 0.330 |
Why?
| | Delivery of Health Care | 1 | 2017 | 954 | 0.330 |
Why?
| | Mutation | 2 | 2019 | 4053 | 0.320 |
Why?
| | Dietary Supplements | 3 | 2019 | 587 | 0.320 |
Why?
| | Metabolomics | 4 | 2024 | 715 | 0.310 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2010 | 105 | 0.310 |
Why?
| | Waiting Lists | 4 | 2024 | 255 | 0.310 |
Why?
| | Cimicifuga | 2 | 2019 | 2 | 0.300 |
Why?
| | Computational Biology | 4 | 2025 | 677 | 0.300 |
Why?
| | Transforming Growth Factor alpha | 1 | 2009 | 57 | 0.300 |
Why?
| | Transplant Recipients | 4 | 2024 | 183 | 0.290 |
Why?
| | Mutagenicity Tests | 4 | 2025 | 16 | 0.290 |
Why?
| | Databases, Factual | 5 | 2024 | 1465 | 0.280 |
Why?
| | Everolimus | 2 | 2025 | 111 | 0.270 |
Why?
| | Mycophenolic Acid | 2 | 2025 | 121 | 0.270 |
Why?
| | Genomics | 4 | 2023 | 831 | 0.260 |
Why?
| | Tacrolimus | 2 | 2025 | 200 | 0.260 |
Why?
| | Infant, Newborn | 11 | 2025 | 6366 | 0.250 |
Why?
| | Computer Simulation | 4 | 2021 | 1028 | 0.250 |
Why?
| | Formaldehyde | 2 | 2018 | 66 | 0.250 |
Why?
| | Transforming Growth Factor beta | 1 | 2009 | 484 | 0.240 |
Why?
| | Ventricular Function, Left | 3 | 2022 | 520 | 0.240 |
Why?
| | Plant Extracts | 2 | 2018 | 212 | 0.240 |
Why?
| | Rats | 10 | 2025 | 5610 | 0.240 |
Why?
| | Survival Rate | 4 | 2025 | 2003 | 0.230 |
Why?
| | Animals | 24 | 2025 | 38010 | 0.230 |
Why?
| | Incidence | 4 | 2025 | 2844 | 0.230 |
Why?
| | Interleukin-6 | 1 | 2009 | 781 | 0.220 |
Why?
| | Alkanesulfonic Acids | 1 | 2025 | 49 | 0.220 |
Why?
| | Stroke Volume | 4 | 2022 | 607 | 0.220 |
Why?
| | Time Factors | 6 | 2025 | 7031 | 0.220 |
Why?
| | Biotransformation | 1 | 2024 | 62 | 0.210 |
Why?
| | Aflatoxin B1 | 2 | 2014 | 3 | 0.210 |
Why?
| | Animal Testing Alternatives | 2 | 2021 | 3 | 0.210 |
Why?
| | DNA | 2 | 2019 | 1457 | 0.210 |
Why?
| | Multivariate Analysis | 4 | 2019 | 1510 | 0.200 |
Why?
| | Adverse Outcome Pathways | 1 | 2023 | 4 | 0.200 |
Why?
| | Proportional Hazards Models | 4 | 2019 | 1292 | 0.200 |
Why?
| | Dose-Response Relationship, Drug | 6 | 2025 | 2056 | 0.200 |
Why?
| | Vasoplegia | 1 | 2022 | 5 | 0.190 |
Why?
| | Fluorocarbons | 1 | 2025 | 141 | 0.190 |
Why?
| | Heart Injuries | 1 | 2023 | 41 | 0.190 |
Why?
| | Spike Glycoprotein, Coronavirus | 1 | 2024 | 125 | 0.190 |
Why?
| | Consensus | 2 | 2025 | 550 | 0.190 |
Why?
| | Muscular Dystrophies | 1 | 2022 | 33 | 0.190 |
Why?
| | Extracellular Vesicles | 1 | 2025 | 162 | 0.190 |
Why?
| | Hep G2 Cells | 2 | 2025 | 74 | 0.190 |
Why?
| | Rodentia | 1 | 2022 | 59 | 0.180 |
Why?
| | American Heart Association | 2 | 2021 | 302 | 0.180 |
Why?
| | Ginkgo biloba | 2 | 2018 | 10 | 0.180 |
Why?
| | Adult | 12 | 2024 | 40013 | 0.180 |
Why?
| | Organisation for Economic Co-Operation and Development | 1 | 2021 | 2 | 0.180 |
Why?
| | Hepatocytes | 2 | 2019 | 219 | 0.170 |
Why?
| | Structure-Activity Relationship | 3 | 2017 | 576 | 0.170 |
Why?
| | Databases, Chemical | 2 | 2019 | 9 | 0.170 |
Why?
| | Clinical Protocols | 1 | 2022 | 279 | 0.170 |
Why?
| | Pesticides | 1 | 2021 | 63 | 0.170 |
Why?
| | Coronary Vessels | 2 | 2021 | 251 | 0.160 |
Why?
| | Practice Patterns, Physicians' | 2 | 2021 | 1362 | 0.160 |
Why?
| | Echinacea | 1 | 2019 | 2 | 0.160 |
Why?
| | Adjustment Disorders | 1 | 2019 | 5 | 0.160 |
Why?
| | Age Factors | 4 | 2021 | 3328 | 0.160 |
Why?
| | Quantitative Structure-Activity Relationship | 2 | 2017 | 19 | 0.160 |
Why?
| | Arsenites | 1 | 2019 | 6 | 0.150 |
Why?
| | Stents | 1 | 2023 | 543 | 0.150 |
Why?
| | Spironolactone | 1 | 2019 | 33 | 0.150 |
Why?
| | Cohort Studies | 5 | 2024 | 5891 | 0.150 |
Why?
| | Logistic Models | 1 | 2024 | 2107 | 0.150 |
Why?
| | Kaplan-Meier Estimate | 3 | 2017 | 921 | 0.150 |
Why?
| | Mineralocorticoid Receptor Antagonists | 1 | 2019 | 55 | 0.150 |
Why?
| | Cell Transformation, Neoplastic | 2 | 2019 | 341 | 0.150 |
Why?
| | Ultrasonography, Interventional | 1 | 2020 | 158 | 0.150 |
Why?
| | United States | 9 | 2022 | 15553 | 0.150 |
Why?
| | Food Contamination | 1 | 2018 | 54 | 0.150 |
Why?
| | Gene Amplification | 1 | 2019 | 108 | 0.140 |
Why?
| | Eugenol | 1 | 2018 | 4 | 0.140 |
Why?
| | Liver Transplantation | 1 | 2026 | 814 | 0.140 |
Why?
| | Fontan Procedure | 1 | 2021 | 184 | 0.140 |
Why?
| | Tissue Fixation | 1 | 2018 | 36 | 0.140 |
Why?
| | Ultrasonography | 2 | 2020 | 769 | 0.140 |
Why?
| | Paraffin Embedding | 1 | 2018 | 32 | 0.140 |
Why?
| | Coronary Angiography | 1 | 2020 | 318 | 0.140 |
Why?
| | DNA, Neoplasm | 1 | 2018 | 162 | 0.140 |
Why?
| | HEK293 Cells | 2 | 2018 | 748 | 0.140 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2019 | 258 | 0.140 |
Why?
| | Prostate | 1 | 2019 | 173 | 0.140 |
Why?
| | Mice, Inbred Strains | 1 | 2018 | 408 | 0.140 |
Why?
| | Isoantibodies | 1 | 2017 | 57 | 0.130 |
Why?
| | Cryopreservation | 1 | 2018 | 107 | 0.130 |
Why?
| | Cell Culture Techniques | 2 | 2017 | 375 | 0.130 |
Why?
| | Global Health | 1 | 2020 | 387 | 0.130 |
Why?
| | Patient Selection | 1 | 2021 | 691 | 0.130 |
Why?
| | Uniparental Disomy | 1 | 2017 | 9 | 0.130 |
Why?
| | Anesthesia, Dental | 1 | 2017 | 22 | 0.130 |
Why?
| | Donor Selection | 1 | 2017 | 78 | 0.130 |
Why?
| | Epigenomics | 1 | 2017 | 115 | 0.130 |
Why?
| | Tooth Extraction | 1 | 2017 | 28 | 0.130 |
Why?
| | Research Design | 2 | 2023 | 1123 | 0.130 |
Why?
| | Bundle-Branch Block | 1 | 2017 | 32 | 0.130 |
Why?
| | Gene Expression | 2 | 2019 | 1505 | 0.130 |
Why?
| | Arsenic | 1 | 2017 | 64 | 0.130 |
Why?
| | Muscular Diseases | 1 | 2017 | 113 | 0.130 |
Why?
| | Longitudinal Studies | 1 | 2024 | 3006 | 0.130 |
Why?
| | Artificial Intelligence | 1 | 2021 | 365 | 0.130 |
Why?
| | Education, Medical, Continuing | 1 | 2017 | 128 | 0.120 |
Why?
| | Depressive Disorder | 1 | 2019 | 376 | 0.120 |
Why?
| | Reproducibility of Results | 3 | 2021 | 3380 | 0.120 |
Why?
| | HLA Antigens | 1 | 2017 | 232 | 0.120 |
Why?
| | DNA Repair | 2 | 2019 | 250 | 0.120 |
Why?
| | Models, Chemical | 1 | 2017 | 273 | 0.120 |
Why?
| | Systems Biology | 1 | 2016 | 73 | 0.120 |
Why?
| | Diagnosis, Differential | 1 | 2020 | 1504 | 0.120 |
Why?
| | Trisomy | 1 | 2017 | 78 | 0.120 |
Why?
| | Anesthesia, General | 1 | 2017 | 116 | 0.120 |
Why?
| | Cluster Analysis | 1 | 2017 | 526 | 0.120 |
Why?
| | Oligonucleotide Array Sequence Analysis | 3 | 2018 | 763 | 0.120 |
Why?
| | Health Services Needs and Demand | 1 | 2017 | 282 | 0.120 |
Why?
| | Models, Theoretical | 1 | 2019 | 586 | 0.120 |
Why?
| | Glucocorticoids | 1 | 2020 | 537 | 0.120 |
Why?
| | Multicenter Studies as Topic | 2 | 2023 | 389 | 0.120 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2017 | 146 | 0.120 |
Why?
| | Neuromuscular Diseases | 1 | 2017 | 146 | 0.110 |
Why?
| | Gene-Environment Interaction | 2 | 2017 | 191 | 0.110 |
Why?
| | Pharmaceutical Preparations | 1 | 2017 | 173 | 0.110 |
Why?
| | Aromatase Inhibitors | 1 | 2015 | 58 | 0.110 |
Why?
| | Heme Oxygenase-1 | 1 | 2015 | 72 | 0.110 |
Why?
| | Receptors, Estrogen | 1 | 2018 | 425 | 0.110 |
Why?
| | Equipment Failure | 1 | 2015 | 112 | 0.110 |
Why?
| | Biomarkers, Pharmacological | 1 | 2014 | 26 | 0.110 |
Why?
| | RNA, Messenger | 3 | 2024 | 2852 | 0.110 |
Why?
| | Perioperative Care | 1 | 2017 | 234 | 0.110 |
Why?
| | Freezing | 1 | 2014 | 88 | 0.110 |
Why?
| | Rats, Inbred F344 | 1 | 2014 | 265 | 0.110 |
Why?
| | Vaccination | 4 | 2024 | 1484 | 0.100 |
Why?
| | Cell Survival | 1 | 2017 | 1136 | 0.100 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2023 | 1671 | 0.100 |
Why?
| | Crohn Disease | 1 | 2017 | 256 | 0.100 |
Why?
| | Cell Membrane | 1 | 2017 | 708 | 0.100 |
Why?
| | Adrenergic alpha-2 Receptor Agonists | 1 | 2013 | 24 | 0.100 |
Why?
| | Hospitals, Pediatric | 1 | 2017 | 557 | 0.100 |
Why?
| | Dexmedetomidine | 1 | 2013 | 43 | 0.100 |
Why?
| | Propensity Score | 1 | 2015 | 350 | 0.100 |
Why?
| | Drug Administration Schedule | 1 | 2015 | 773 | 0.100 |
Why?
| | Proteome | 1 | 2017 | 494 | 0.100 |
Why?
| | Hemodynamics | 2 | 2018 | 1117 | 0.090 |
Why?
| | Epithelial Cells | 1 | 2019 | 1125 | 0.090 |
Why?
| | Disease Progression | 1 | 2020 | 2856 | 0.090 |
Why?
| | Genetic Diseases, Inborn | 1 | 2012 | 46 | 0.090 |
Why?
| | Quality Improvement | 1 | 2021 | 1263 | 0.090 |
Why?
| | Heart | 2 | 2022 | 632 | 0.090 |
Why?
| | Anxiety | 1 | 2019 | 1090 | 0.090 |
Why?
| | Hospitalization | 1 | 2022 | 2313 | 0.090 |
Why?
| | Respiratory Insufficiency | 1 | 2015 | 325 | 0.090 |
Why?
| | Models, Genetic | 1 | 2014 | 593 | 0.090 |
Why?
| | Mental Disorders | 1 | 2020 | 1151 | 0.090 |
Why?
| | Kidney Diseases | 1 | 2015 | 412 | 0.090 |
Why?
| | Drug Therapy, Combination | 2 | 2025 | 1058 | 0.090 |
Why?
| | Patient Acceptance of Health Care | 1 | 2017 | 884 | 0.080 |
Why?
| | Recovery of Function | 1 | 2015 | 702 | 0.080 |
Why?
| | Antibody Formation | 2 | 2022 | 297 | 0.080 |
Why?
| | Healthcare Disparities | 1 | 2017 | 691 | 0.080 |
Why?
| | Propanolamines | 1 | 2010 | 40 | 0.080 |
Why?
| | Oxidative Stress | 1 | 2017 | 1370 | 0.080 |
Why?
| | Carbazoles | 1 | 2010 | 57 | 0.080 |
Why?
| | Pediatrics | 1 | 2018 | 1124 | 0.080 |
Why?
| | Prognosis | 3 | 2018 | 4152 | 0.080 |
Why?
| | Predictive Value of Tests | 2 | 2017 | 2086 | 0.080 |
Why?
| | Sensitivity and Specificity | 2 | 2014 | 1984 | 0.080 |
Why?
| | Signal Transduction | 3 | 2018 | 5214 | 0.080 |
Why?
| | Cell Proliferation | 1 | 2017 | 2542 | 0.080 |
Why?
| | Statistics, Nonparametric | 1 | 2010 | 434 | 0.080 |
Why?
| | Carcinogenicity Tests | 2 | 2022 | 10 | 0.070 |
Why?
| | Chi-Square Distribution | 1 | 2010 | 527 | 0.070 |
Why?
| | Surveys and Questionnaires | 2 | 2022 | 6025 | 0.070 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2010 | 228 | 0.070 |
Why?
| | Antibodies, Viral | 2 | 2024 | 666 | 0.070 |
Why?
| | MicroRNAs | 1 | 2015 | 698 | 0.070 |
Why?
| | Survival Analysis | 1 | 2011 | 1332 | 0.070 |
Why?
| | Transplantation, Homologous | 1 | 2009 | 414 | 0.070 |
Why?
| | Biological Assay | 2 | 2018 | 128 | 0.070 |
Why?
| | Cardiomyopathy, Hypertrophic, Familial | 1 | 2007 | 15 | 0.070 |
Why?
| | RNA | 1 | 2014 | 933 | 0.070 |
Why?
| | Renin-Angiotensin System | 1 | 2007 | 78 | 0.060 |
Why?
| | Receptors, Aryl Hydrocarbon | 2 | 2019 | 57 | 0.060 |
Why?
| | Genotype | 2 | 2009 | 1877 | 0.060 |
Why?
| | Rats, Sprague-Dawley | 2 | 2024 | 2531 | 0.060 |
Why?
| | Neoplasms | 1 | 2022 | 2804 | 0.060 |
Why?
| | Polymerase Chain Reaction | 1 | 2009 | 1062 | 0.060 |
Why?
| | Hemofiltration | 1 | 2006 | 23 | 0.060 |
Why?
| | Biopsy | 1 | 2009 | 1083 | 0.060 |
Why?
| | Lymphoproliferative Disorders | 1 | 2025 | 60 | 0.060 |
Why?
| | ROC Curve | 2 | 2019 | 603 | 0.060 |
Why?
| | Exons | 2 | 2019 | 359 | 0.060 |
Why?
| | Caprylates | 1 | 2025 | 27 | 0.060 |
Why?
| | Polymorphism, Genetic | 1 | 2007 | 626 | 0.050 |
Why?
| | Aged | 2 | 2023 | 25322 | 0.050 |
Why?
| | Catheterization, Peripheral | 1 | 2006 | 116 | 0.050 |
Why?
| | Catheterization, Central Venous | 1 | 2006 | 117 | 0.050 |
Why?
| | Gene Regulatory Networks | 2 | 2019 | 319 | 0.050 |
Why?
| | Cytomegalovirus Infections | 1 | 2025 | 199 | 0.050 |
Why?
| | Middle Aged | 3 | 2023 | 35342 | 0.050 |
Why?
| | Workflow | 1 | 2025 | 178 | 0.050 |
Why?
| | Ventricular Outflow Obstruction | 1 | 2023 | 40 | 0.050 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2018 | 2575 | 0.050 |
Why?
| | Prospective Studies | 4 | 2020 | 7899 | 0.050 |
Why?
| | Cell Line | 2 | 2019 | 2897 | 0.050 |
Why?
| | Organophosphates | 1 | 2024 | 184 | 0.050 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2018 | 549 | 0.050 |
Why?
| | Hypertension, Pulmonary | 1 | 2013 | 1957 | 0.040 |
Why?
| | Vaccines, Synthetic | 1 | 2022 | 139 | 0.040 |
Why?
| | Antibodies | 1 | 2024 | 402 | 0.040 |
Why?
| | Bias | 1 | 2022 | 208 | 0.040 |
Why?
| | Replantation | 1 | 2021 | 31 | 0.040 |
Why?
| | Mice | 3 | 2025 | 18378 | 0.040 |
Why?
| | Prosthesis Design | 1 | 2023 | 352 | 0.040 |
Why?
| | Insurance Coverage | 1 | 2022 | 240 | 0.040 |
Why?
| | Data Accuracy | 1 | 2021 | 64 | 0.040 |
Why?
| | Mammals | 1 | 2022 | 291 | 0.040 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2022 | 198 | 0.040 |
Why?
| | Social Class | 1 | 2022 | 273 | 0.040 |
Why?
| | Carcinogenesis | 1 | 2022 | 232 | 0.040 |
Why?
| | Cells, Cultured | 2 | 2019 | 4182 | 0.040 |
Why?
| | Exercise Tolerance | 1 | 2022 | 285 | 0.040 |
Why?
| | PPAR alpha | 1 | 2019 | 57 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2022 | 5743 | 0.040 |
Why?
| | Documentation | 1 | 2021 | 194 | 0.040 |
Why?
| | Carcinogens, Environmental | 1 | 2019 | 14 | 0.040 |
Why?
| | Cricetulus | 1 | 2019 | 111 | 0.040 |
Why?
| | CHO Cells | 1 | 2019 | 166 | 0.040 |
Why?
| | Primary Cell Culture | 1 | 2019 | 171 | 0.040 |
Why?
| | Chickens | 1 | 2019 | 190 | 0.040 |
Why?
| | Prevalence | 1 | 2026 | 2830 | 0.040 |
Why?
| | DNA Breaks, Double-Stranded | 1 | 2019 | 49 | 0.040 |
Why?
| | Micronucleus Tests | 1 | 2018 | 7 | 0.040 |
Why?
| | Therapeutic Equivalency | 1 | 2018 | 32 | 0.040 |
Why?
| | Anemia, Megaloblastic | 1 | 2018 | 9 | 0.040 |
Why?
| | Micronuclei, Chromosome-Defective | 1 | 2018 | 8 | 0.040 |
Why?
| | Hyperplasia | 1 | 2018 | 174 | 0.040 |
Why?
| | Magnetic Resonance Imaging, Cine | 1 | 2019 | 211 | 0.030 |
Why?
| | Myocardial Contraction | 1 | 2019 | 300 | 0.030 |
Why?
| | Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2018 | 40 | 0.030 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2019 | 209 | 0.030 |
Why?
| | Muscular Dystrophy, Emery-Dreifuss | 1 | 2017 | 3 | 0.030 |
Why?
| | Myopathies, Structural, Congenital | 1 | 2017 | 5 | 0.030 |
Why?
| | Mass Spectrometry | 1 | 2021 | 740 | 0.030 |
Why?
| | Muscular Dystrophies, Limb-Girdle | 1 | 2017 | 6 | 0.030 |
Why?
| | Barth Syndrome | 1 | 2017 | 8 | 0.030 |
Why?
| | Activation, Metabolic | 1 | 2017 | 5 | 0.030 |
Why?
| | International Cooperation | 1 | 2018 | 195 | 0.030 |
Why?
| | Phytotherapy | 1 | 2018 | 82 | 0.030 |
Why?
| | Antidepressive Agents | 1 | 2019 | 243 | 0.030 |
Why?
| | Myotonic Dystrophy | 1 | 2017 | 10 | 0.030 |
Why?
| | HCT116 Cells | 1 | 2017 | 80 | 0.030 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2018 | 198 | 0.030 |
Why?
| | Chromosomes, Human, Pair 9 | 1 | 2017 | 41 | 0.030 |
Why?
| | Brazil | 1 | 2017 | 177 | 0.030 |
Why?
| | Infliximab | 1 | 2017 | 111 | 0.030 |
Why?
| | Hazardous Substances | 1 | 2016 | 15 | 0.030 |
Why?
| | Gastrointestinal Agents | 1 | 2017 | 67 | 0.030 |
Why?
| | Molecular Conformation | 1 | 2017 | 147 | 0.030 |
Why?
| | Sample Size | 1 | 2017 | 126 | 0.030 |
Why?
| | Death | 1 | 2017 | 128 | 0.030 |
Why?
| | Databases, Genetic | 1 | 2018 | 248 | 0.030 |
Why?
| | Folic Acid | 1 | 2018 | 199 | 0.030 |
Why?
| | Mosaicism | 1 | 2017 | 76 | 0.030 |
Why?
| | United Kingdom | 1 | 2017 | 334 | 0.030 |
Why?
| | DNA Methylation | 1 | 2021 | 667 | 0.030 |
Why?
| | Lab-On-A-Chip Devices | 1 | 2016 | 59 | 0.030 |
Why?
| | Friedreich Ataxia | 1 | 2017 | 78 | 0.030 |
Why?
| | Pulsatile Flow | 1 | 2016 | 55 | 0.030 |
Why?
| | Echocardiography, Transesophageal | 1 | 2017 | 131 | 0.030 |
Why?
| | Canada | 1 | 2017 | 433 | 0.030 |
Why?
| | Mortality | 1 | 2018 | 364 | 0.030 |
Why?
| | Comorbidity | 1 | 2020 | 1678 | 0.030 |
Why?
| | Health Care Surveys | 1 | 2017 | 565 | 0.030 |
Why?
| | Biomarkers, Tumor | 1 | 2022 | 1282 | 0.030 |
Why?
| | MCF-7 Cells | 1 | 2015 | 130 | 0.030 |
Why?
| | Catheters | 1 | 2015 | 74 | 0.030 |
Why?
| | Colonoscopy | 1 | 2017 | 254 | 0.030 |
Why?
| | Cardiotonic Agents | 1 | 2015 | 95 | 0.030 |
Why?
| | Peroxisome Proliferator-Activated Receptors | 1 | 2014 | 17 | 0.030 |
Why?
| | Kidney Tubules, Proximal | 1 | 2015 | 128 | 0.030 |
Why?
| | Double-Blind Method | 1 | 2019 | 2017 | 0.030 |
Why?
| | Drugs, Investigational | 1 | 2014 | 31 | 0.030 |
Why?
| | Tissue Donors | 1 | 2017 | 412 | 0.030 |
Why?
| | Gene Library | 1 | 2014 | 123 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2015 | 346 | 0.030 |
Why?
| | Organ Specificity | 1 | 2014 | 311 | 0.030 |
Why?
| | Area Under Curve | 1 | 2014 | 327 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2021 | 3625 | 0.030 |
Why?
| | Flow Cytometry | 1 | 2017 | 1192 | 0.030 |
Why?
| | Electrocardiography | 1 | 2017 | 630 | 0.030 |
Why?
| | Glucuronosyltransferase | 1 | 2013 | 17 | 0.030 |
Why?
| | Promoter Regions, Genetic | 1 | 2018 | 1263 | 0.020 |
Why?
| | E2F1 Transcription Factor | 1 | 2013 | 72 | 0.020 |
Why?
| | Radiation Effects | 1 | 2012 | 7 | 0.020 |
Why?
| | Genetic Variation | 1 | 2018 | 1008 | 0.020 |
Why?
| | Principal Component Analysis | 1 | 2013 | 198 | 0.020 |
Why?
| | Erythrocytes | 1 | 2018 | 708 | 0.020 |
Why?
| | Alternative Splicing | 1 | 2014 | 243 | 0.020 |
Why?
| | Acute Disease | 1 | 2015 | 1015 | 0.020 |
Why?
| | Models, Molecular | 1 | 2017 | 1622 | 0.020 |
Why?
| | Estradiol | 1 | 2015 | 525 | 0.020 |
Why?
| | Precancerous Conditions | 1 | 2013 | 165 | 0.020 |
Why?
| | Germ-Line Mutation | 1 | 2012 | 173 | 0.020 |
Why?
| | Testosterone | 1 | 2015 | 423 | 0.020 |
Why?
| | Tobacco Products | 1 | 2012 | 91 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2019 | 3611 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2018 | 2936 | 0.020 |
Why?
| | Quality of Life | 1 | 2022 | 3080 | 0.020 |
Why?
| | Heart Ventricles | 1 | 2015 | 755 | 0.020 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2013 | 365 | 0.020 |
Why?
| | Attitude of Health Personnel | 1 | 2017 | 1207 | 0.020 |
Why?
| | Lung | 1 | 2021 | 4101 | 0.020 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2007 | 120 | 0.020 |
Why?
| | Echocardiography, Doppler | 1 | 2007 | 113 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2013 | 1487 | 0.020 |
Why?
| | Leukocytes, Mononuclear | 1 | 2009 | 589 | 0.020 |
Why?
| | DNA Primers | 1 | 2007 | 518 | 0.020 |
Why?
| | Gene Frequency | 1 | 2007 | 492 | 0.020 |
Why?
| | Subclavian Vein | 1 | 2006 | 15 | 0.020 |
Why?
| | Pregnancy | 1 | 2017 | 7153 | 0.010 |
Why?
| | Alleles | 1 | 2007 | 893 | 0.010 |
Why?
| | Base Sequence | 1 | 2007 | 2199 | 0.010 |
Why?
| | Phenotype | 1 | 2007 | 3211 | 0.010 |
Why?
|
|
Auerbach's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|